scm logo

SCM Life Science, a company specializing in cell therapy (SCM Life Science, CEO Lee Byung-gun. KOSDAQ 298060) announced on the 26th that patents related to pharmaceutical compositions for the treatment of transplant host diseases (hereinafter GVHD), including clonal stem cells, have been registered. The duration is until 2039.

This patent shows improved effects in clinical symptoms when single-clonal stem cells obtained using improved layer separation culture are administered to mice induced to develop GVHD, ▲ survival rate ▲ dead skin ▲ blood clots ▲ hair condition ▲ ascites ▲ diarrhea ▲ etc.

GVHD is a common disease in the process of organ transplantation or bone marrow transplantation, and in severe cases, immune cells in the transplanted organ or blood attack patients who have undergone organ transplantation or bone marrow transplantation, which can lead to death.

The improved layer separation culture method, a key technology in SCM Life Science, is evaluated as an innovative technology that can obtain large amounts of high-purity stem cells through low-density culture and antioxidant addition in the process of mass production of stem cells.

In particular, it is attracting attention from the pharmaceutical bio-industry as it can prevent cell aging that occurs commonly in the stem cell culture process.

Currently, SCM Life Science is conducting a phase 2 clinical trial of GVHD based on the patent, and was designated as rare drug in the development stage in 2019. In 2023, it is planned to enter the market after obtaining conditional approval for the product.

An official from SCM Life Science said, "We have confirmed the improved effects of GVHD symptoms using improved layer separation culture, and expect the excellent effects of GVHD treatments under development," adding, "As the patent technology is scheduled to be applied overseas in early June, the decision is expected to have a positive impact on the global screening process."